Most addiction treatment providers know the SUPPORT Act exists. Few understand what it actually changed in their day-to-day operations.
If you're billing Medicare or Medicaid for substance use disorder treatment, operating an opioid treatment program, or prescribing medication-assisted treatment, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) Act fundamentally altered your compliance obligations, billing opportunities, and reimbursement landscape. Signed into law in October 2018, this wasn't just another policy statement about the opioid crisis. It rewrote Medicare coverage rules for OTPs, modified Medicaid's IMD exclusion, eliminated the X-waiver for buprenorphine prescribing, and introduced new program integrity requirements that directly increase your compliance exposure.
This article breaks down what the SUPPORT Act means for addiction treatment providers who need to understand the operational changes, not the political talking points.
What the SUPPORT Act Changed for Addiction Treatment Providers
The SUPPORT Act contains over 70 provisions spanning prevention, treatment, recovery, and enforcement. For treatment providers billing federal payers, three categories matter most: Medicare coverage expansions, Medicaid treatment flexibilities, and program integrity requirements.
Before the SUPPORT Act, Medicare didn't cover opioid treatment program services at all. Medicaid's IMD exclusion blocked federal matching funds for most residential treatment for adults aged 21-64. Buprenorphine prescribing required a special DEA X-waiver with patient limits. The SUPPORT Act addressed each of these barriers while simultaneously tightening enrollment and oversight requirements for providers billing Medicare and Medicaid for substance use disorder treatment.
The result: expanded billing opportunities paired with heightened compliance scrutiny. Operators who don't understand both sides of that equation leave money on the table or expose themselves to audit risk.
Medicare OTP Benefit Expansion: What Opioid Treatment Programs Can Now Bill
The most significant operational change for many providers is the Medicare Part B coverage of opioid treatment program services, effective January 1, 2020. For the first time, OTPs can bill Medicare for medication-assisted treatment using methadone or buprenorphine.
Medicare reimburses OTP services through a bundled weekly payment structure. The bundle includes the opioid agonist or antagonist medication, dispensing and administration, substance use counseling, individual and group therapy, toxicology testing, intake activities, and periodic assessments. Providers bill using HCPCS codes in the G2067-G2080 range, with different codes reflecting the specific medication, take-home doses, and service intensity.
To qualify for Medicare reimbursement, your OTP must be SAMHSA-certified, state-licensed, and enrolled as a Medicare supplier. You need a National Provider Identifier, a PTAN, and documentation that your program meets the federal opioid treatment standards in 42 CFR Part 8. Understanding the bundled billing structure is critical because improper unbundling or billing for services already included in the weekly rate is a common compliance error.
For new OTPs, this Medicare benefit creates a viable payer mix that didn't exist before 2020. For existing programs, it requires billing system updates, staff training on Medicare documentation requirements, and compliance protocols that account for Medicare's stricter audit standards compared to state-funded or cash-pay models.
Medicaid SUD Treatment Changes Under the SUPPORT Act
The SUPPORT Act modified Medicaid's Institution for Mental Diseases (IMD) exclusion in ways that matter for residential treatment providers. Historically, the IMD exclusion prohibited federal Medicaid matching funds for care provided in facilities with more than 16 beds that primarily treat mental health or substance use disorders for patients aged 21-64.
Section 1003 of the SUPPORT Act allows states to receive federal Medicaid matching funds for residential SUD treatment in IMD settings for up to 30 days per year for adults in Medicaid expansion populations. This isn't automatic coverage. It requires states to submit a state plan amendment or Section 1115 waiver demonstrating compliance with specific requirements around evidence-based treatment, use of medication-assisted treatment, and coordination with community-based providers.
What this means operationally: if you run a residential program with more than 16 beds in a state that has implemented this provision, you can now bill Medicaid for eligible patients within the 30-day annual limit. But you need to verify your state's implementation status, understand the specific coverage criteria your state adopted, ensure your program meets the evidence-based treatment standards required for reimbursement, and track the 30-day limit per beneficiary per year.
State-level variability is significant. Some states implemented this quickly with broad coverage. Others have been slower or imposed additional restrictions. Your billing and intake processes need to account for which patients qualify under your state's specific rules. Expanding treatment accessibility requires understanding these state-by-state differences.
Buprenorphine Prescribing Authority Changes: The X-Waiver Elimination
The SUPPORT Act initially expanded buprenorphine prescribing authority to nurse practitioners and physician assistants, a change that reshaped clinical staffing models at many treatment centers. But the more significant shift came later when the Consolidated Appropriations Act of 2023 eliminated the X-waiver requirement entirely, building on the foundation the SUPPORT Act established.
As of December 2022, any DEA-registered practitioner who can prescribe controlled substances can prescribe buprenorphine for opioid use disorder without obtaining a separate waiver or completing special training. The previous patient limits (30, 100, or 275 patients) no longer apply. SAMHSA's updated guidance clarifies that practitioners must still comply with applicable state laws and should receive training on treating opioid use disorder, but the federal waiver barrier is gone.
For treatment programs, this changes clinical capacity planning. You no longer need to limit MAT prescribing to waivered providers or manage patient caps. But you still need protocols ensuring prescribers are competent in addiction medicine, documentation supporting medical necessity for buprenorphine treatment, and compliance with state-specific requirements that may exceed federal standards.
This also affects credentialing and payor enrollment. While the X-waiver is gone, Medicare and Medicaid still require proper enrollment and credentialing for practitioners billing for MAT services. Your compliance infrastructure needs to track which providers are enrolled with which payers and ensure documentation meets federal and state standards for MAT prescribing.
Program Integrity Provisions That Increase Compliance Exposure
The SUPPORT Act didn't just expand coverage. It also introduced new program integrity requirements specifically targeting behavioral health and addiction treatment providers.
Key provisions include enhanced screening for Medicare and Medicaid enrollment, mandatory site visits for certain provider types before enrollment approval, increased penalties for false statements on enrollment applications, and expanded authority for moratoria on new provider enrollments in geographic areas with fraud concerns.
CMS has used this authority aggressively in behavioral health. Several regions have experienced enrollment moratoria for new substance use disorder treatment facilities. Site visit requirements add time and complexity to the enrollment process. Enhanced screening means your enrollment application receives closer scrutiny, and any discrepancies in ownership, financial relationships, or prior sanctions can delay or deny enrollment.
For operators, this means enrollment timelines are longer and less predictable. You need complete documentation of ownership structure, financial relationships with referral sources, and compliance history before you apply. Any prior disciplinary actions, excluded individuals in your organization, or undisclosed financial interests can trigger denial.
The SUPPORT Act also strengthened provisions around telehealth for substance use disorder treatment, but with guardrails. While telehealth expansion has been significant, particularly post-pandemic, the Act included language ensuring appropriate safeguards against fraud and abuse in telehealth SUD treatment. Providers offering telehealth MAT need documentation supporting medical necessity, compliance with state telehealth laws, and protocols preventing diversion.
What Addiction Treatment Providers Need to Audit Right Now
If you're billing Medicare or Medicaid for substance use disorder treatment, here's what you need to review to ensure SUPPORT Act compliance and maximize available reimbursement.
Provider Enrollment and Credentialing: Verify that all practitioners prescribing MAT are properly enrolled with Medicare and Medicaid. Confirm your OTP has current SAMHSA certification and state licensure if billing the Medicare OTP benefit. Check that your enrollment applications reflect current ownership and financial relationships.
Billing Codes and Documentation: If you're an OTP billing Medicare, ensure you're using the correct HCPCS G-codes for bundled services and not unbundling components already included in the weekly rate. Review your documentation to confirm it supports the level of service billed and includes required elements like individualized treatment plans, counseling notes, and medication monitoring. Understanding proper coding for detox and MAT services prevents claim denials and audit exposure.
MAT Protocols: Update your clinical protocols to reflect current buprenorphine prescribing authority. Ensure your policies address prescriber competency, patient assessment standards, monitoring for diversion, and coordination with pharmacy partners. Document training for prescribers on opioid use disorder treatment even though the X-waiver is eliminated.
State-Specific Medicaid Rules: If you provide residential treatment, confirm whether your state has implemented the IMD exclusion modification and understand the specific coverage criteria. Update your intake and billing processes to identify eligible patients and track the 30-day annual limit.
Program Integrity Compliance: Review your referral relationships for any arrangements that could be construed as inducements under federal anti-kickback statutes. The heightened scrutiny on behavioral health means referral relationships that might have been overlooked before now carry significant risk. Ensure your marketing, patient brokering, and referral practices comply with federal and state laws.
Many operators underestimate the complexity of maintaining compliance across these requirements while also managing clinical operations. The administrative burden of credentialing, billing, documentation audits, and regulatory updates diverts attention from patient care and business growth.
Frequently Asked Questions About the SUPPORT Act for Treatment Providers
Can all opioid treatment programs bill Medicare now?
Only OTPs that are SAMHSA-certified, state-licensed, and enrolled as Medicare suppliers can bill Medicare Part B for OTP services. You need to complete the Medicare enrollment process, obtain a PTAN, and meet all federal opioid treatment standards in 42 CFR Part 8. Simply being a licensed treatment provider isn't sufficient.
Does the SUPPORT Act eliminate the IMD exclusion for Medicaid?
No, it modifies the exclusion to allow federal Medicaid matching funds for up to 30 days per year of residential SUD treatment in IMD settings for certain populations. States must implement this through a state plan amendment or waiver, and many have additional requirements. The exclusion still applies outside these specific circumstances.
Do I still need an X-waiver to prescribe buprenorphine?
No. As of December 2022, the X-waiver requirement was eliminated. Any DEA-registered practitioner who can prescribe controlled substances can prescribe buprenorphine for opioid use disorder without a separate waiver. However, practitioners must still comply with state laws and should have appropriate training in treating opioid use disorder.
What are the biggest compliance risks the SUPPORT Act created for treatment providers?
The enhanced program integrity provisions increase enrollment scrutiny, site visit requirements, and penalties for enrollment violations. Treatment providers face higher audit risk, particularly around referral relationships, billing accuracy for bundled OTP services, and documentation supporting medical necessity. Operators need stronger compliance infrastructure than before 2018.
How do the SUPPORT Act changes interact with other recent federal policy updates?
The SUPPORT Act is one piece of an evolving regulatory landscape. Recent changes to telehealth rules, the Consolidated Appropriations Act provisions on buprenorphine, and ongoing Medicaid demonstrations all build on the SUPPORT Act foundation. Staying current on federal policy changes is critical for maintaining compliance and maximizing reimbursement opportunities.
Should I handle SUPPORT Act compliance and billing in-house or outsource it?
The complexity of Medicare OTP billing, Medicaid state-by-state variations, enhanced program integrity requirements, and ongoing regulatory changes makes in-house management challenging for many operators. Outsourcing billing and compliance functions to specialists who track regulatory updates and maintain payer relationships often reduces errors, accelerates reimbursement, and lowers audit risk.
Let ForwardCare Handle the Compliance and Billing Complexity
The SUPPORT Act expanded billing opportunities for addiction treatment providers, but it also increased compliance complexity and audit exposure. Navigating Medicare OTP enrollment, state-specific Medicaid rules, program integrity requirements, and evolving MAT regulations requires specialized expertise that most clinical operators don't have in-house.
ForwardCare is a behavioral health management services organization that handles the business infrastructure, credentialing, billing, and compliance operations for addiction treatment providers. We manage Medicare and Medicaid enrollment, ensure accurate coding and documentation for OTP bundled services, track state-by-state Medicaid implementation, and maintain compliance protocols that reduce audit risk.
Our team stays current on regulatory changes so you can focus on clinical care and program growth without navigating federal payer rules alone. If you're operating an OTP, prescribing MAT, or running an IOP, PHP, or residential program billing Medicare or Medicaid, we provide the operational infrastructure to maximize reimbursement while maintaining compliance.
Learn more about how ForwardCare supports addiction treatment providers at forwardcare.com.
